Skip to main content
Top
Published in: Supportive Care in Cancer 7/2018

01-07-2018 | Original Article

The TEACHH model to predict life expectancy in patients presenting for palliative spine radiotherapy: external validation and comparison with alternate models

Authors: Maryam Dosani, Scott Tyldesley, Brendan Bakos, Jeremy Hamm, Tim Kong, Sarah Lucas, Jordan Wong, Mitchell Liu, Sarah Hamilton

Published in: Supportive Care in Cancer | Issue 7/2018

Login to get access

Abstract

Introduction

The TEACHH score was developed to identify patients with predicted short (< 3 months) and long (> 1 year) life expectancy. We aimed to validate this model in an independent group of patients presenting for palliative spine radiotherapy and to compare it to alternate prognostic models.

Methods

We retrospectively reviewed charts of 195 consecutive patients referred for palliative spine radiotherapy. Patients were grouped according to the number of risk factors from the TEACHH model, Chow model, and Oswestry Risk Index.

Results

One hundred and eighty patients with a median age of 65 years were included. Follow-up was 5.8 months in all patients and 31.8 months in living patients.
For the TEACHH model, patients in groups 1, 2, and 3 had a median (95% CI) overall survival (OS) of 22.3 (15.7–36.1), 4.9 (3.8–6.6), and 1.5 (0.8–5.4) months, respectively. Wilcoxon pairwise comparisons showed statistically different survival between groups 1 and 2, and 1 and 3. In the Chow model, patients in groups 1, 2, and 3 had a median (95% CI) OS of 16.1 (10.0–22.3), 5.9 (3.8–9.2), and 1.9 (1.2–2.5) months, respectively. There was a significant difference between all groups. The Oswestry Risk Index identified five prognostic groups with median OS (95% CI) ranging from 22.2 (12.9–30.2) to 2.1 (0.8–4.0) months. Only group 1 was statistically different from the others.
Although the effect of age was small, the TEACHH model performed best with the inclusion of all parameters.

Conclusions

The TEACHH model is useful to identify patients with spinal metastases with predicted short, intermediate, and long LE. Its prognostic ability is similar to the Chow model.
Appendix
Available only for authorised users
Literature
2.
go back to reference Chow E, Harth T, Hruby G, Finkelstein J, Wu J, Danjoux C (2001) How accurate are physicians’ clinical predictions of survival and the available prognostic tools in estimating survival times in terminally ill cancer patients? A systematic review. Clin Oncol 13(3):209–218. https://doi.org/10.1053/clon.2001.9256 CrossRef Chow E, Harth T, Hruby G, Finkelstein J, Wu J, Danjoux C (2001) How accurate are physicians’ clinical predictions of survival and the available prognostic tools in estimating survival times in terminally ill cancer patients? A systematic review. Clin Oncol 13(3):209–218. https://​doi.​org/​10.​1053/​clon.​2001.​9256 CrossRef
17.
23.
go back to reference Pirovano M, Maltoni M, Nanni O, Marinari M, Indelli M, Zaninetta G et al (1999) A new palliative prognostic score: a first step for the staging of terminally ill cancer patients. Italian Multicenter and Study Group on Palliative Care. J Pain Symptom Manag 17:231–239CrossRef Pirovano M, Maltoni M, Nanni O, Marinari M, Indelli M, Zaninetta G et al (1999) A new palliative prognostic score: a first step for the staging of terminally ill cancer patients. Italian Multicenter and Study Group on Palliative Care. J Pain Symptom Manag 17:231–239CrossRef
Metadata
Title
The TEACHH model to predict life expectancy in patients presenting for palliative spine radiotherapy: external validation and comparison with alternate models
Authors
Maryam Dosani
Scott Tyldesley
Brendan Bakos
Jeremy Hamm
Tim Kong
Sarah Lucas
Jordan Wong
Mitchell Liu
Sarah Hamilton
Publication date
01-07-2018
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 7/2018
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-018-4064-x

Other articles of this Issue 7/2018

Supportive Care in Cancer 7/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine